How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,010 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. [A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue]. (Abstract)

[A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue]. Benign prostatic hyperplasia (BPH) is the most common proliferative disease of the prostate gland in the elderly.The results of an open, randomized comparative study of the effectiveness of Serenoa repens in the combination with Urtica dioiccus (...) , an increase in Qmax, a decrease in postvoid residual urine volume and an intensity of the inflammatory process in the prostatic tissue. However, in patients with BPH associated with chronic inflammation, it is preferable to use Serenoa repens in combination with Urtica dioiccus.

2019 Urologii︠a︡ (Moscow, Russia : 1999) Controlled trial quality: uncertain

102. E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer. Full Text available with Trip Pro

E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer. We previously reported the presence of prostate-specific antigen (PSA) in the stromal compartment of benign prostatic hyperplasia (BPH). Since PSA is expressed exclusively by prostatic luminal epithelial cells, PSA in the BPH stroma suggests increased tissue permeability and the compromise of epithelial barrier integrity. E (...) . In vitro cell line studies using benign prostatic epithelial cell lines were performed to determine the impact of small interfering RNA knockdown of E-cadherin on transepithelial electrical resistance and diffusion of fluorescein isothiocyanate (FITC)-dextran in transwell assays.The number of kiss points in tight junctions was reduced in BPH epithelial cells as compared with the normal adjacent prostate. Immunostaining confirmed E-cadherin downregulation and revealed a discontinuous E-cadherin staining

2019 Prostate

103. Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150cc): 1-year Results. Full Text available with Trip Pro

Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150cc): 1-year Results. To report 12-month safety and effectiveness outcomes of the Aquablation procedure for the treatment of men with symptomatic BPH and large-volume prostates.101 men with moderate-to-severe BPH symptoms and prostate volumes of 80-150cc underwent a robotic-assisted Aquablation procedure in a prospective multicenter international clinical trial. Functional and safety outcomes were assessed at 12 months (...) postoperatively.Mean prostate volume was 107cc (range 80-150). Mean operative time was 37 minutes and mean Aquablation resection time was 8 minutes. The average length of hospital stay following the procedure was 1.6 days. Mean IPSS improved from 23.2 at baseline to 6.2 at 12 months (p<.0001). Mean IPSS quality of life improved from 4.6 at baseline to 1.3 at 12-month follow-up (p<.0001). Significant improvements were seen in Qmax (12-month improvement of 12.5 cc/sec) and post-void residual (drop of 171 cc in those

2019 Urology

104. Monopolar enucleation versus transurethral resection of the prostate for small- and medium-sized (&lt; 80 cc) benign prostate hyperplasia: a prospective analysis. (Abstract)

Monopolar enucleation versus transurethral resection of the prostate for small- and medium-sized (< 80 cc) benign prostate hyperplasia: a prospective analysis. To assess efficacy and safety of monopolar enucleation of the prostate (MEP) and to compare it with the current treatment standard for medium-sized prostates, < 80 cc, transurethral resection of the prostate (TURP).A prospective analysis patients undergoing a surgical procedure for their diagnosis of BPH (benign prostatic hyperplasia (...) was 1.7 and 3.2 days for TURP (p < 0.001). Hospital stay for MEP was 3.2 days vs. 4.8 days for TURP (p < 0.001). Both techniques shown comparable efficiency in benign prostatic obstruction relief with IPSS drop in MEP from 23.1 to 5.9 and in TURP group from 22.8 to 7.3, whereas Qmax increased from 8.2 to 20.5 after MEP and from 8.3 and 19.9 after TURP. Urinary incontinence rate after catheter removal in TURP group was 9.0% and 7.8% in MEP group, at 1 year follow-up, it was 1.4% and 3.1% in MEP

2019 World journal of urology

105. Factors influencing intraoperative blood loss in patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP) for Benign Prostatic Hyperplasia: a large multicenter analysis. (Abstract)

Factors influencing intraoperative blood loss in patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP) for Benign Prostatic Hyperplasia: a large multicenter analysis. To assess blood loss during holmium laser enucleation of the prostate (HoLEP) and investigate the factors influencing it.analysis of patients with benign prostatic hyperplasia (BPH) treated with HoLEP at three centres. Haemoglobin and haematocrit were measured before surgery and hospital discharge. All blood (...) transfusions performed during and after HoLEP were recorded. Blood loss outcomes were analysed regarding antithrombotic (antiplatelet/anticoagulant) therapies and drug treatments for BPH and other conditions.The analysis included 963 patients with a mean age of 72 years. Mean (range) prostate size was 102 (40-316) g; 28% of patients were receiving antiplatelets and 11% anticoagulants. Mean (range) prostate-specific antigen was 6.0 (0.3-43.5) ng/dL. Mean (range) operation time was 77 (28-178) min. Bladder

2019 Urology

106. 1470 nm Diode Laser Enucleation vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study. Full Text available with Trip Pro

1470 nm Diode Laser Enucleation vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study. The purpose of the current work was to comparatively assess 1470 nm diode laser enucleation of the prostate (DiLEP) and plasmakinetic resection of the prostate (PKRP) for treating benign prostatic hyperplasia (BPH).From January 2016 to March 2017, 157 individuals with bladder outflow obstruction caused by BPH were randomized to DiLEP and PKRP groups, for prospective (...) decrease was markedly less pronounced after DiLEP (P = 0.004). However, no patients needed blood transfusion in either group. The decrease in sodium level showed no marked differences between the DiLEP and PKRP groups (P = 0.380). In addition, complications were comparable and no significant differences in both groups. At 3, 6, and 12 months, International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), and postvoid residual (PVR) were similar in both groups (P > 0.05

2019 Journal of Endourology Controlled trial quality: uncertain

107. Editorial Comment on: 1470 nm Diode Laser Enucleation vs Plasmakinetic Bipolar Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study by Zhang et al. (From: Zhang J, Wang X, Zhang Y, et al. J Endourol 2019;33:211-217; DOI: 10.108 (Abstract)

Editorial Comment on: 1470 nm Diode Laser Enucleation vs Plasmakinetic Bipolar Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study by Zhang et al. (From: Zhang J, Wang X, Zhang Y, et al. J Endourol 2019;33:211-217; DOI: 10.108 30572717 2019 11 20 1557-900X 33 3 2019 Mar Journal of endourology J. Endourol. Editorial Comment on: 1470 nm Diode Laser Enucleation vs Plasmakinetic Bipolar Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study

2019 Journal of Endourology Controlled trial quality: uncertain

108. Prostate artery embolisation for benign prostatic hyperplasia. Full Text available with Trip Pro

Prostate artery embolisation for benign prostatic hyperplasia. 29921580 2019 03 12 2019 03 12 1756-1833 361 2018 Jun 19 BMJ (Clinical research ed.) BMJ Prostate artery embolisation for benign prostatic hyperplasia. k2537 10.1136/bmj.k2537 Challacombe Ben B Departments of Urology and Interventional Radiology, Guy's and St Thomas Hospitals NHS Foundation Trust, London SE1 9RT, UK benchallacombe@doctors.org.uk. Sabharwal Tarun T Departments of Urology and Interventional Radiology, Guy's and St (...) Thomas Hospitals NHS Foundation Trust, London SE1 9RT, UK. eng Comparative Study Editorial Multicenter Study Observational Study Randomized Controlled Trial 2018 06 19 England BMJ 8900488 0959-8138 AIM IM Decision Making Embolization, Therapeutic adverse effects methods Humans Lasers, Solid-State therapeutic use Male Prostate blood supply pathology Prostatic Hyperplasia diagnostic imaging therapy Urinary Bladder Neck Obstruction physiopathology Urodynamics Vascular Surgical Procedures methods

2019 BMJ (Clinical research ed.) Controlled trial quality: uncertain

109. Prostatic Artery Embolization for Benign Prostatic Hyperplasia: Prospective Randomized Trial of 100-300 μm versus 300-500 μm versus 100- to 300-μm + 300- to 500-μm Embospheres. (Abstract)

Prostatic Artery Embolization for Benign Prostatic Hyperplasia: Prospective Randomized Trial of 100-300 μm versus 300-500 μm versus 100- to 300-μm + 300- to 500-μm Embospheres. This study compared the safety and efficacy of prostatic arterial embolization (PAE) with that of trisacryl gelatin microspheres of different sizes for treatment of benign prostatic hyperplasia (BPH).This study consisted of a single-center, randomized controlled clinical trial in 138 patients who underwent PAE (...) for BPH between July 2015 and December 2016. Patients were randomized to PAE using microspheres of different sizes: group A patients were treated with microspheres 100-300 μm, group B with 300-500 μm, and group C with 100-300 μm followed by 300-500 μm. All patients were evaluated before and at 1, 3, 6, 12, and 18 months after PAE. Baseline data were comparable across the 3 groups, using the following mean International Prostate Symptom Score/quality of life (IPSS/QoL); prostate volume (PV) scores

2019 Journal of vascular and interventional radiology : JVIR Controlled trial quality: uncertain

110. Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. Full Text available with Trip Pro

Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. Benign prostatic hyperplasia (BPH) is an age-related disease, affecting a majority of elderly men worldwide. Medical management of BPH is an alternative to surgical treatment of this disease. Currently, α1-adrenergic receptor (α1-AR) antagonists are among the first line drugs to treat BPH by reducing the tension of urinary track and thus the obstructive symptoms

2018 PLoS ONE

111. GreenLight XPS for treating benign prostatic hyperplasia

GreenLight XPS for treating benign prostatic hyperplasia GreenLight XPS for treating benign GreenLight XPS for treating benign prostatic h prostatic hyperplasia yperplasia Medical technologies guidance Published: 14 June 2016 nice.org.uk/guidance/mtg29 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful (...) for treating benign prostatic hyperplasia (MTG29) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 30Contents Contents 1 Recommendations 4 2 The technology 5 Description of the technology 5 Current management 6 3 Clinical evidence 8 Summary of clinical evidence 8 4 NHS considerations 16 System impact 16 5 Cost considerations 18 Cost evidence 18 6 Conclusions 24 7 Committee members and NICE lead team 25 Medical

2016 National Institute for Health and Clinical Excellence - Medical technologies

112. The UK ROPE Study: efficacy and safety of prostate artery embolisation for benign prostatic hyperplasia. An observational study and propensity matched comparison with transurethral resection of the prostate. Full Text available with Trip Pro

The UK ROPE Study: efficacy and safety of prostate artery embolisation for benign prostatic hyperplasia. An observational study and propensity matched comparison with transurethral resection of the prostate. To assess the efficacy and safety of prostate artery embolization (PAE) for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and to conduct an indirect comparison of PAE with transurethral resection of the prostate (TURP).As a joint initiative between (...) the British Society of Interventional Radiologists, the British Association of Urological Surgeons and the National Institute for Health and Care Excellence, we conducted the UK Register of Prostate Embolization (UK-ROPE) study, which recruited 305 patients across 17 UK urological/interventional radiology centres, 216 of whom underwent PAE and 89 of whom underwent TURP. The primary outcomes were International Prostate Symptom Score (IPSS) improvement in the PAE group at 12 months post-procedure

2018 BJU international

113. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia Full Text available with Trip Pro

Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia Background: Prostate cancer (PCa) represents the second most commonly diagnosed malignancy and the sixth leading cause for cancer related death among men worldwide. Although use of the prostate specific antigen (PSA) as a diagnostic marker has improved the detection and management of PCa, low specificity and sensitivity has limited its (...) clinical efficacy. Moreover, elevated PSA is frequently observed in benign prostate hyperplasia (BPH). Mean platelet volume (MPV) and platelet distribution width (PDW) are commonly used indicators of platelet activation. The purpose of current study was to investigate the ability of PSA, MPV, and PDW individually or in combination, to differentiate PCa from BPH. Materials and Methods: This study included 100 patients with PCa and 108 patients with BPH. We collected all participants’ clinical

2018 Asian Pacific journal of cancer prevention : APJCP

114. Prostate specific antigen and relative prostate weight data on effect of Tetracarpidium conophorum leaf extract on testosterone-induced benign prostatic hyperplasia Full Text available with Trip Pro

Prostate specific antigen and relative prostate weight data on effect of Tetracarpidium conophorum leaf extract on testosterone-induced benign prostatic hyperplasia Benign prostatic hyperplasia (BPH) is a common urological disorder of men, characterized by prostatic enlargement and urethral obstruction. In this study, BPH was induced in experimental groups by daily subcutaneous injections of testosterone propionate (TP) for 3 weeks. Tetracarpidium conophorum was administered daily by oral (...) gavage at a dose of 100, 200 and 400 mg/kg BW of extract for three weeks, along with the TP injections and 5 mg/kg of finasteride for comparison. On day 21, the animals were sacrificed after anesthesia. Prostate were excised, weighed and used to determine relative prostate weight. Quantitative and qualitative phytochemical screening was also done and it showed the presence of flavonoids (0.370 mg/ml), tannins (0.458 mg/ml), phenols (0.508 mg/ml) and steroids (0.257 mg/ml). The prostate specific

2018 Data in brief

115. Comparison of &lt; 100 cc prostates and &gt; 100 cc prostates undergoing aquablation for benign prostatic hyperplasia. (Abstract)

Comparison of < 100 cc prostates and > 100 cc prostates undergoing aquablation for benign prostatic hyperplasia. Surgical options for benign prostatic hyperplasia (BPH) become limited when treating large prostates due to steep learning curves and less effective treatment. Aquablation (AquaBeam System, PROCEPT BioRobotics, Inc., USA) could remedy this. We compare the effectiveness of Aquablation in large prostates between 80 cc and 100 cc and very large prostates > 100 cc.WATER II (...) (NCT03123250) is a prospective, multicenter, international clinical trial of Aquablation for the surgical treatment of LUTS/BPH in men of age 45-80 years with prostates between 80 cc and 150 cc. Aquablation was performed using the AquaBeam System. The reported analysis compares the subgroup of patients with a baseline prostate size of < 100 cc versus those with a prostate size of > 100 cc. Students' t test was used for continuous variables and Fisher's test for ordinal/binary variables.Of 114 screened

2018 World journal of urology

116. Prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: protocol for a non-inferiority clinical trial Full Text available with Trip Pro

Prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: protocol for a non-inferiority clinical trial Benign prostatic hyperplasia (BPH) is a prevalent disease associated with lower urinary tract symptoms (LUTS). The standard of care for moderate-to-severe LUTS unresponsive to pharmacological treatment is the transurethral resection of the prostate (TURP). However, this intervention is not exempt from complications (...) . Prostatic artery embolization (PAE) has been described as a new, effective and safe procedure for the treatment of LUTS secondary to BPH. To date, only one clinical trial has been published on the use of PAE for LUTS, but the study was methodologically flawed in terms of safety monitoring. Therefore, well-designed clinical studies are required to compare the efficacy and safety of both techniques in the treatment of LUTS secondary to BPH.This was a prospective, randomized, non-inferiority clinical trial

2018 Research and reports in urology Controlled trial quality: uncertain

117. A prospective pilotstudy comparing the anesthetic effects of an alpha-2 agonist during holmium laser resection of the prostate and transurethral resection for prostate surgery for benign prostatic hyperplasia patients using selective alpha-1 blockers. Full Text available with Trip Pro

A prospective pilotstudy comparing the anesthetic effects of an alpha-2 agonist during holmium laser resection of the prostate and transurethral resection for prostate surgery for benign prostatic hyperplasia patients using selective alpha-1 blockers. To examine the response to an α2receptor agonist used as a sedative for patients using long-term selective α1 blockers.Sixty-nine consecutive patients undergoing transurethral prostate resection or holmium laser resection of the prostateunder (...) loading dose injection of dexmedetomidine. Differencesbetween both groupswere noted at 15 min(group T: 100.2 ± 12.9 mmHg; group N: 90.0 ± 17.5 mmHg; P = 0.08), 20 min (group T: 99.8 ± 12.3 mmHg; group N: 87.4 ± 15.0 mmHg; P < 0.00), 25 min (group T: 99.3 ± 13.4 mmHg; group N: 85.4 ± 13.8 mmHg; P < 0.00), and 30 min (group T: 98.8 ± 13.1 mmHg; group N: 84.5 ± 13.5 mmHg; P < 0.00).The use of α2 agonists is appropriate during surgery for benign prostatic hyperplasia patients using tamsulosin

2018 BMC Anesthesiology

118. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia

UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia UroLift for treating lower urinary tr UroLift for treating lower urinary tract act symptoms of benign prostatic symptoms of benign prostatic h hyperplasia yperplasia Medical technologies guidance Published: 16 September 2015 nice.org.uk/guidance/mtg26 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) of implementing NICE recommendations wherever possible. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG26) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 35Contents Contents 1 Recommendations 4 2 The technology 5 Description of the technology 5 Current management 6 3 Clinical evidence 8 Summary of clinical evidence 8 4 NHS considerations 21 System impact 21 5 Cost considerations 23

2015 National Institute for Health and Clinical Excellence - Medical technologies

119. Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia

Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia TITLE: Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia: Comparative Clinical Effectiveness and Safety DATE: 07 March 2014 RESEARCH QUESTIONS 1. What is the comparative clinical effectiveness and safety of dutasteride and finasteride for men with benign prostatic hyperplasia? 2. What is the clinical effectiveness and safety of dutasteride versus placebo for men with benign prostatic hyperplasia? 3. What (...) is the clinical effectiveness and safety of finasteride versus placebo for men with benign prostatic hyperplasia? KEY MESSAGE Four systematic reviews and six randomized controlled trials were found regarding the clinical effectiveness and safety of dutasteride and finasteride compared to each other or placebo for the treatment of benign prostatic hyperplasia. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 2), University of York Centre

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

120. Photoselective vaporization versus transurethral resection of the prostate for benign prostatic hyperplasia: a meta-analysis

Photoselective vaporization versus transurethral resection of the prostate for benign prostatic hyperplasia: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>